View Older Stories View More Recent Stories

Dec 2, 2025 08:01AM DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
Nov 18, 2025 08:01AM Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
Nov 12, 2025 08:01AM Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
Nov 10, 2025 08:01AM Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
Oct 15, 2025 09:01AM Mainz Biomed to Attend 2025 Maxim Growth Summit
Oct 8, 2025 09:00AM Mainz Biomed reports 100% sensitivity in pancreatic cancer test study
Oct 8, 2025 09:00AM Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Sep 30, 2025 08:01AM Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
Sep 23, 2025 08:01AM Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Sep 2, 2025 08:02AM Mainz Biomed receives UK regulatory approval for ColoAlert cancer test
Sep 2, 2025 08:01AM Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
Aug 13, 2025 08:02AM Mainz Biomed receives swiss approval for ColoAlert cancer screening test
Aug 13, 2025 08:01AM Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
Jul 23, 2025 08:01AM Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
Jul 15, 2025 08:01AM Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Jun 25, 2025 08:01AM Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
Jun 10, 2025 09:01AM Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
May 16, 2025 08:02AM Mainz Biomed (MYNZ) Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
May 16, 2025 08:01AM Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
Apr 29, 2025 08:01AM Mainz Biomed Enters into Technology Partnership with EDX Medical Group
Apr 28, 2025 08:01AM Mainz Biomed (MYNZ) Provides Q1 Corporate Update and Path to FDA Premarket Approval
Apr 28, 2025 08:01AM Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Apr 1, 2025 08:01AM Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Mar 27, 2025 09:01AM Mainz Biomed (MYNZ) Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Mar 27, 2025 09:01AM Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Mar 13, 2025 08:01AM Mainz Biomed (MYNZ) and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
Mar 13, 2025 08:01AM Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
Mar 3, 2025 08:01AM Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
Feb 20, 2025 08:01AM Mainz Biomed Expands into Switzerland with labor team w
Feb 11, 2025 08:01AM Mainz Biomed (MYNZ) and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening
Feb 11, 2025 08:01AM Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Jan 27, 2025 08:01AM Mainz Biomed (MYNZ) Regains Nasdaq Compliance
Jan 27, 2025 08:01AM Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Jan 27, 2025 08:01AM Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Jan 21, 2025 08:01AM Mainz Biomed (MYNZ) Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
Jan 21, 2025 08:01AM Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
Dec 19, 2024 08:03AM Mainz Biomed (MYNZ) Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Dec 19, 2024 08:01AM Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Nov 12, 2024 09:00AM Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
Oct 21, 2024 08:02AM Mainz Biomed (MYNZ) Reports Mid-Year 2024 Financial Results, Provides Corporate Update
Oct 21, 2024 08:01AM Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Oct 8, 2024 08:01AM Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
Oct 1, 2024 08:02AM Mainz Biomed (MYNZ) CEO Issues Update
Oct 1, 2024 08:01AM Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Sep 18, 2024 08:01AM Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Sep 4, 2024 07:10AM Mainz Biomed (MYNZ) Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
Sep 4, 2024 04:01AM Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
Jul 25, 2024 08:03AM Mainz Biomed (MYNZ) Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Jul 25, 2024 08:01AM Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Jul 9, 2024 05:39AM Mainz Biomed (MYNZ) Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
View More Recent Stories View Older Stories